Current Report Filing (8-k)
April 12 2017 - 1:40PM
Edgar (US Regulatory)
|
UNITED STATES
|
SECURITIES AND EXCHANGE COMMISSION
|
WASHINGTON, DC 20549
|
|
|
FORM 8-K
|
|
CURRENT REPORT PURSUANT
|
TO SECTION 13 OR 15(D) OF THE
|
SECURITIES EXCHANGE ACT OF 1934
|
|
Date of report (Date of earliest event reported):
April 12, 2017
|
|
BIOTRICITY INC.
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Nevada
|
|
333-201719
|
|
47-2548273
|
(State or Other Jurisdiction of Incorporation or Organization)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
275 Shoreline Drive, Suite 150
Redwood City, California 94065
|
|
94065
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code: (416) 214-3678
|
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Item 7.01
|
Regulation FD Disclosure
|
On April 12, 2017, Biotricity, Inc., a Nevada corporation (the Registrant), announced that it has filed for a second and final 510(k) for the hardware portion of its Bioflux solution with the U.S. Food and Drug Administration.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
|
|
Item 9.01
|
Financial Statements and Exhibits
|
(d)
Exhibits
. The exhibit listed in the following Exhibit Index are furnished as part of this Current Report on Form 8-K:
|
|
|
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: April 12, 2017
|
|
|
|
BIOTRICITY INC.
|
|
|
|
|
By:
|
/s/ Waqaas Al-Siddiq
|
|
|
Waqaas Al-Siddiq
|
|
|
Chief Executive Officer
|
3